News from NORD

Letter to Congress: NORD and Others Oppose “Right to Try”


 

NORD and 40 other patient organizations and professional societies have sent a letter to the leadership of the US House of Representatives explaining why they oppose “Right to Try” legislation currently being considered by Congress. Signers of the letter include the American Society of Clinical Oncology, Leukemia & Lymphoma Society, American Lung Association, and National Health Council. The organizations say they support patients being given access to unapproved therapies but believe the bills under consideration will not increase patient access.

Recommended Reading

Visit NORD’s Website to Learn About Current or Future Research Funding Opportunities
MDedge Neurology
NORD Launches Year-Long 35th Anniversary Observance
MDedge Neurology
NORD Provides Update on Tax Cuts and Jobs Act
MDedge Neurology
FDA Issues Guidance for More Efficient Approach to Drug Development for Rare Pediatric Diseases
MDedge Neurology
NIH Undiagnosed Diseases Network to Offer Grand Rounds Webinar Series
MDedge Neurology
Genetic Screens Yield Potential Therapies for Neurodegenerative Diseases
MDedge Neurology
Can Newborn Screening for Krabbe Disease Lead to New Therapies?
MDedge Neurology
Mogamulizumab active in HTLV-1–associated myelopathy
MDedge Neurology
NORD to Moderate Panel at NIH Rare Disease Day Event
MDedge Neurology
Rare Disease Day Events Planned for Campuses, Hospitals, and State Legislatures
MDedge Neurology